Zepbound (Tirzepatide) Use During Breastfeeding

Clinical Considerations

• The American Academy of Pediatrics and other medical societies suggest that large molecular weight peptides, like tirzepatide, typically have limited transfer into breast milk, but this cannot be assumed without specific lactation studies 1
• The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis recommends considering alternative medications with established breastfeeding safety profiles, such as insulin or metformin, if tirzepatide is used for type 2 diabetes 1
• The American College of Obstetricians and Gynecologists advises that weight loss interventions, including tirzepatide for obesity management, should generally be deferred during lactation given the lack of urgent medical necessity 2
• The National Institute for Health and Care Excellence suggests that the absence of evidence is not evidence of safety, and the precautionary principle applies when no lactation data exists, as is the case with tirzepatide 3, 2, 4, 5